Respiratorius
Notice of allowance of patent application for VAL001
REG
The patent application allowed by the Canadian Intellectual Property Office is the first patent application on the formulation from Respiratorius, claiming a novel oral formulation of sodium valproate for pretreating cancer. The priority date of the patent application is 21 April 2016 which will be in force at least 20 years from the priority date granting market exclusivity. The application in the same patent family was allowed and issued in Japan during 2022.
This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 12-10-2023 08:29 CET.
| Datum | 2023-10-12, kl 08:29 |
| Källa | Cision |
Kopiera toppinvesterare! Med eToros innovativa CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för att använda CopyTrader-funktionen.
Copy Trading innebär inte investeringsråd. Värdet på dina investeringar kan gå upp eller ned. Ditt kapital löper risk.